Results 71 to 80 of about 3,401,781 (173)

First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer [PDF]

open access: yes, 2019
Introduction: Cytokine release syndrome (CRS) is a potentially life-threatening systemic disease that has been observed after treatment with antibodies and adoptive T cell therapies.
Yoshihiro Miyahara   +11 more
core   +1 more source

Anakinra after Initial Tocilizumab Doses for Cytokine Release Syndrome (CRS)

open access: yesTransplantation and Cellular Therapy, 2022
Ailin Jennifer Kim   +4 more
openaire   +1 more source

Cytokine Release Syndrome: Current Perspectives

open access: yesImmunoTargets and Therapy, 2019
Hemant Murthy,1 Madiha Iqbal,1 Julio C Chavez,2 Mohamed A Kharfan-Dabaja1 1Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa,
Murthy H   +3 more
doaj  

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden

open access: yesOncoImmunology
Immune checkpoint inhibitors (ICIs) are linked to diverse immune-related adverse events (irAEs). Rare irAEs surface first in clinical practice. Here, we systematically studied the rare irAE, cytokine-release syndrome (CRS), in a cohort of 2672 patients ...
Osama Hamida   +4 more
doaj   +1 more source

Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy [PDF]

open access: yes
Cytokine release syndrome (CRS) is a frequently observed side effect of chimeric antigen receptor (CAR)-T cell therapy. Here, we report self-regulating T cells that reduce CRS severity by secreting inhibitors of cytokines associated with CRS.
Ceja, Melanie Ayala   +11 more
core   +1 more source

Cytokine Release Syndrome - CRS General Review

open access: yesInternational Journal of Science and Research (IJSR), 2023
openaire   +1 more source

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

open access: yesFrontiers in Immunology
PurposeCD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.MethodsThis ...
Qianyi Zhou   +14 more
doaj   +1 more source

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

open access: yes, 2019
Lara L Riegler,1 Gavin P Jones,2 Daniel W Lee1 1Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA, USA; 2School of Medicine, University of Virginia, Charlottesville, VA, USA Abstract: With ...
Jones GP, Lee DW, Riegler LL
core  

Impact of Cytokine Release Syndrome (CRS) in Haplo-Identical Stem Cell Transplantation (Haplo)

open access: yesTransplantation and Cellular Therapy, 2022
Indumathy Varadarajan   +5 more
openaire   +1 more source

Tocilizumab: a therapeutic option for the treatment of Cytokine Storm Syndrome in COVID-19

open access: yes, 2020
Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm
Lee, Sang-Soo   +5 more
core  

Home - About - Disclaimer - Privacy